New developments in the use of cytokines for cancer therapy

Anticancer Research

Volumn 17, Issue 5 B, 1997, Pages 3803-3808

  Maini, Atul ^a   Morse, Philo D ^a   Wang, Ching Y ^a   Jones, Richard F ^a   Haas, Gabriel P ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Cancer; Cytokines; Immunotoxins

Indexed keywords

ANTIBODY; CYTOKINE; HEMOPOIETIC GROWTH FACTOR; IMMUNOTOXIN; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7;

ABDOMINAL PAIN; ADOPTIVE IMMUNOTHERAPY; ANTIBODY PRODUCTION; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; IMMUNOREGULATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTOSIS; LIVER TOXICITY; METASTASIS; MONOCYTOSIS; MYALGIA; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; RIGOR; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; CYTOKINES; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOTOXINS; INTERLEUKINS; NEOPLASMS;

EID: 0031439377     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Hillman GG and Haas GP: Role of cytokines in lymphocyte functions: In: Cytokines: Their role in Disease and Therapy (Aggarwal BB, and Puri RK, eds). Cambridge MA, Blackwell Science 1995 pp 37-54.
2. Dinarello CA: Biology of interleukin 1. FASEB J 2: 108-115, 1988.
3. Dinarello CA: Interleukin 1 and interleukin-1 antagonism. Blood 77: 1627-1652, 1991.
4. Crown J, Gabrilove J, Kemmeny N, Sheridan C, Jakubowski A, Sinha S, Gasperrato C, Toner G, Shieh JH, Meisenberg B, Gordon M, Botet J, Zakowski M, Houstan C, Dantis L, Cheney P, Buhles W, Moore M and Kelson D: Phase I and II trial of recombinant human interleukin 1 in patients with metastatic colorectal cancer receiving myelosuppresive doses of 5-fluorouracil. Proc Am Soc Clin.Oncol 19: 183, 1990.
5. Crown J, Kemmeny N, Jakubowski A, Sheridan C, Gasperrato C, Toner G, Meisenberg B, Abboud M, Sinha S, Gordon M, Houstan C, Oettgan H, Buhles W, Wong G, Cheney T, Moore M, Kelson D and Gabrilove J: Phase I and II trial of recombinant human interleukin 1 (IL-1) in patients with metastatic colorectal cancer receiving myelosuppresive doses of 5-fluorouracil. Blood 74: 43, 1989.
6. Kitamura T and Takaku F: A preclinical trial and phase I clinical trial of IL-1. Exp Med 7: 170-177, 1989.
7. Dennis D, Chachoua A, Caron D, Garrison L, Liebes L, Furmanski P, Wiprovnick J, Peace D, Oratz R, Speyer J and Blum RH: Biologic activity of interleukin 1 (IL-1) alpha in patients with refractomy malignancies. Proc Am Assoc Clin Oncol: 11: 255, 1992.
8. Tewari A, Williams BJr, and Fletcher Jr: Preliminary report: Effect of interleukin 1 on the platelet counts. Lancet 336: 712-714, 1996.
9. Fletcher HS Jr: Biological effects and possible clinical applications of interleukinl. Seminars in Hematology 28: 34-41, 1991.
10. Smith JW II, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, Sznol M, Creekmore SP, Wells NF, Ruscetti FW, Kellr JR, Hestdal K, Shimuzi M, Rossio J, Alvord WG, Oppenheim JJ and Longo DL: The toxic and hematological effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncology 10: 1141-1152, 1992.
11. Crown J, Jakubowski A, Kemmeny N, Gordon M, Gasperrato C, Wong G, Sheridan C, Toner G, Meisenberg B, Botet J, Applewhite J, Sinha S, Moore M, Kelson D, Buhles W and Gabrilove J: A Phase I trial of recombinant human interleukin 1 alone and in combination with myelosuppresive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 78: 1420-1427, 1991.
12. Puri RK: Structure and function of interleukin-4 and its receptor. In: Cytokines: Interleukins and its Receptors (Kuzrock R ed) Norwell MA, Kluwer Academic Publishers, 1995 pp 143-185.
13. Obiri NI, Siegal JP, Varriccchio F and Puri RK: Expression and function of high affinity inteleukin-4 receptors on human melanoma, ovarialn and breast carcinoma cells. Clin Exp Immun 95: 148-155, 1994.
14. Obiri NI, Hillman GG, Mass GP, Sud S and Puri RK: Expression of high affinity inteleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by IL-4. J Clin Invest 91: 88-93, 1993.
15. Trehu EG, Isner JM, Mier JW, Karp DD and Atkins MB: Possible myocardial toxicity associated with interleukin-4 therapy. J Immunther 14: 348-351, 1993.
16. Rubin JD and Lotze MT: Acute gastric mucosal injury associated with systemic treatment of interleukin-4. Surgery 11: 274-280, 1992.
17. Mahler SJ, Villez RL and Pulitzer DR: Transient acantholytic dermatosis induced by recombinant human IL-4. J Am Acad Dermat 29: 206-209, 1993
18. Suminami Y, Elder M, Lotze MT and Whiteside TL: In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccines. J of Immunotherapy with emphasis on tumor immunology. 17: 238-248, 1995.
19. Hirano T, Akiras, Taga T and Kishimoto T: Biological and clinical aspects of IL-6. Immunology Today 11: 443-449, 1990.
20. Mule JJ, Mcintosh JK, Jablons DM and Rosenberg SA: Antitumor activity of recombinant interleukin-6 in mice. J Exp Med 171: 629-636, 1990.
21. Asano S, Okano A, Ozawa K, Nakashata T, Ishibashi T, Koike K, Kimura H, Tanioka Y, Shibuya A, Hirano T, Kishimoto T, Takaku F and Akiyama Y: In vivo effects of recombinant human interleukin-6 in primates: Stimulated production of platelets. Blood 75: 1602-1605, 1990.
22. Geissler K, Valent P, Bettelheim P, Sillaber C, Wagner B, Kyrle P, Hinterberger W, Lechner K and Mayer P: In vivo synergism of recombinant interleukin 3 and recombinant interleukin 6 on thrombopoiesis in primates. Blood 79: 1155-1160, 1992.
23. Rozmiarek SK, McClure HM, Leihl E, Myers LA and Winton EF: Studies in human primates on the pathogenesis of rHu IL-6 related anemia. Proc Am Assoc Clin Oncol 13: 89A, 1994.
24. Weber J, Young JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, Levin R and Rosenberg SA: Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Onc 11: 499-506, 1993.
25. Hamm J, Crawford J, Figlin R, Chang A, Wasserheit C, Lee M, Campian M, Manfreda S and Isaacs R: Phase I /II study of the simultaneous administration of recombinant human interleukin-6 and Neupogen (rhG-CSF,E.Coli) following ICE chemotherapy in patients with advanced non small cell lung carcinoma. Proc Am Assoc ClinOncol 13: 1100pp332, 1994.
26. Demetri GD, Samuesis B, Gordon M, Merica EA, Mazanet R, Antman KH, Hoffman R, Young DC, Samuel S and Bukowski R: A recombinant human interleukin-6 (IL-6) increases circulating platelet counts and C-reactive protein levels in vivo: initial results of a phase I trial in sarcoma patients with normal hematopoesis. Proc Am Assoc Clin Oncol 13: 88A, 1994.
27. Chang A, Mittelman A, Boros L, Asbury R, Levitt D and Samuel S: Phase I trial of interleukin-6 (IL-6) in cancer patients treated with ifosamide, carboplatin and etoposide (ICE). Proc Am Assoc Clin Oncol 13: 89A, 1994.
28. Mieke M, Gameran V, Willemse PHB, Mulder NH, Limburg PC, Groen HJM, Vellenga E and Elisabeth GE de Vries: Effect of recombinant human interleukin-6 (IL6) in cancer patients: Phase I-II trial study. Blood 84: 1434-1438, 1994.
29. Vander Zee AG, de Cuyper EM, Limburg PC, De Bruijn HW, Hollema H, Bijzet J, Mindret K and deVries GE. Higher levels of Interleukin-6 (IL-6) in cystic fluids from patients with malignant vs benign ovarian tumors correlate with decreased Hemoglobin levels and increased platelet counts. Cancer 75: 1004-1009, 1995.
30. Monti G, Jarand MC, Monnet I, Chretien P, Etienne LP, Zing L, Portier A, Devillier P, Galanaud P, Bignon J and Domnique E: Intrapleural production of interleukin-6 during mesothelioma and its modulation by interferon treatment. Cancer Res 54: 4419-4423, 1994.
31. Ballester OF, Moscinski LN, Lyman GH, Chaney VJ, Saba HI, Spiers ASD and Klein C: Higher levels of Interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 83: 1903-1908, 1994.
32. Hickman CJ, Crim JA and Motowski HS: Regulation of cytotoxic human T lymphocyte development by IL-7. J Immunol 145: 2415-2420 1990.
33. Naume B and Espevic T: Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study. J Immunol 147: 2208-2214, 1991.
34. Schandendorf D, Czarnetki BM and Wittig B: Interleukin-7, interleukin-12 and GM-CSF gene transfer in patients with metastatic melanoma. J Mol Med 73: 473-477, 1995.
35. Goldman S, Loebelanz J, McCarthy K, Hayes L, Neben T, Soudermine J and Schaub R: Recombinant human interleukin-11 (rhIL-11) stimulates megakaryocyte maturation and increase in peripheral platelet number in vivo. Blood 78: 518a, 1991.
36. Gordon MS, Stevens WJ, Battiato LA, Loewy J, Loesh D, Breeden E, Hoffman R, Beach KJ, Bernice K, Kaye J and Sledge GW Jr: A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth) in women with breast cancer receiving chemotherapy. Blood 87: 3615-3624, 1996.
37. Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AYC, Moore JO, Gorden MS, Kuca B, Beach KJ, Loewy JW, Garnick MB and Kaye JA: A randomized placebo controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87: 3607-3614, 1996.
38. Ault KA, Mitchell J, Knowles C, Cleindaniel A, Egan A, Lowey J, Garnick MB and Kaye J: Recombinant human interleukin eleven (Neumega rhIL-11 growth factor) increases plasma volume and decreases urine sodium excretion in normal human subjects. Blood 84: 276a, 1994.
39. Hall S: IL-12 at the crossroads. Science 268: 1432-1434, 1995.
40. Trinchieri G and Gerosa F: Immunoregulation by interleukin-12. J Leukocyte Biol 59: 505-511, 1996.
41. Trinchieri G and Scott P: The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 15: 460-463, 1994.
42. Lamont AG and Adorini L: IL-12: a key cytokine in immune regulation. Immunol Today 17: 214-217, 1996.
43. Jenks S: After initial setback. IL-12 regaining popularity. J Natl Cancer Inst 88: 576577, 1996.
44. Tahara H, Zitvogel L, Storkus W J, Elder E M, Kinzler D, Whiteside T L, Robins PD and Lotze M T: Antitumor effects in patients with melanoma, head and neck and breast cancer in a phase I/II clinical trial of interleukin-12 (IL-12) gene therapy. Proc Am Assoc Clin Oncol 16: 1568, 1997.
45. Herrmann F, Schultz G, Wieser M, Kolbe K, Nicolay U, Noack M, Lindemann A and Mertelsmann R: Effect of granulocyte macrophage colony stimulating factor on neutropenia and related morbidity by myelotoxic chemotherapy induced myelosuppression. N Engl J Med, 319, 1988.
46. Hovgaard DJ and Nissen NI: Effect of granulocyte macrophage colony stimulating factor in patients with Hodgkins disease: A phase I-/II study. J Clin Onc 10: 390-397, 1992.
47. Nemunaitis J, Singer JW, Buckner CD, Hill R, Storb R, Thomas DE and Applebaum FR: Use of recombinant human granulocyte macrophage colony stimulating factor in autologous bone marrow transplantation for lymphoid malignancies. Blood 72: 834-836, 1988.
48. Buchner T and Schultz G: Recombinant human granulocyte macrophage colony stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190-1147, 1991.
49. Jlieschke G, Maher D, Cebon J, Connor OM, Green M, Sheridan W, Boyd A, Rallings M, Bonnem E, Metcalf D, Burgess AW, McGranth K, Fox RM and Morstyn G: Effect of bacterially synthesized recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Annals Int Med. 357364, 1989
50. Thompson JA, Lee DJ, Kidd P, Rubin E, Kauffman J, Bonnem ME and Fefer A: Subcutaneous granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndrome: Toxicity, Pharmakokinetics and Hematological effects. J Clin Onc 7: 629-637, 1989.
51. Ganser A, Volkers, Greher J, Ottman OG, Walther F, Belcher R, Bergman L, Schultz G and Hoeler D: Recombinant human granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndrome: Phase I/II trial. Blood 73: pp 31 -37, 1989.
52. Gianni AM, Siena S, Bregni M7 TarellaC, Stern AC, Pileri A and Bonadonna G: Granulocyte -Macrophage Colony-Stimulating factor to harvest circulating hematopoetic stem cells for autotransplantation. Lancet 9: 580-584, 1989.
53. Bronchud MH: Recombinant human granulocyte colony stimulating factor in the management of cancer patients: Five years on. Oncol 51: 189-197, 1994.
54. Fumimaro T: Clinical applications of cytokines for cancer treatment. Oncol 51: 123-128, 1994.
55. Theur CP and Pastan I: Immunotoxins and recombinant toxins in the treatment of solid carcinomas. Am J Surgery 166: 284-288, 1993.
56. Grossbard ML, Freedman AS, Ritz J, Corel F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambart JM, Blattler WA, Taylor JA and Nadler LM: Serotherapy of B-cell neoplasms with B-4 ricin: A phase I trial of daily bolus infusion. Blood 79: 576-585, 1992.
57. Maini A, Hillman GG, Haas GP, Wang CY, Montecillo E, Hamzavi F, Leland P, Pastan I, Debinski W and Puri RK. Interleukin-13 receptors on human prostate cancer cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J Urol (in press).
58. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastam I, Kreitman RJ. Preclinical development of a recombinant toxin containing circularly permuted interleukin-4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 56: 5631-5637, 1996.